The effects of short-term treatment with the prostaglandin E1 (PGE1) analog misoprostol on inflammatory mediator production in murine lupus nephritis

P. Y. Fan, Phillip Ruiz, D. S. Pisetsky, R. F. Spurney

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

MRL-lpr/lpr mice spontaneously develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus. In these animals, treatment with E-series prostaglandins ameliorates renal disease and prolongs survival, perhaps by modulating production of cytokines or eicosanoids. To further define the mechanisms of action of E-series prostaglandins in established murine lupus nephritis, we administered the prostaglandin E, (PGE1) analog misoprostol to 20-week-old MRL-lpr/lpr mice by twice-daily subcutaneous injection. After 2 days of treatment, misoprostol reduced renal cortical interleukin-1β (IL-1P) mRNA levels compared to vehicle-treated controls (0.19 ± 0.06 (misoprostol) vs 0.50 ± 0.04 (vehicle) densitometry units; P < 0.005). A similar reduction in cortical IL-1P mRNA levels was found in left kidneys harvested from MRL-lpr/lpr mice following 2 days of treatment with misoprostol compared to right kidneys harvested from the same animal prior to the first dose of PGE1, analog (0.12 ± .05 (left) vs 0.39 ± 0.18 (right) densitometry units; P < 0.05). This reduction in cortical IL-1β mRNA levels was not associated with alterations in renal production of thromboxane B2, PGE2, or leukotriene B4 or with significant changes in the severity of renal inflammatory cell infiltrates. Timecourse studies indicated that IL-1P mRNA levels were decreased within 24 hr of initiating misoprostol therapy. This reduction in IL-1β mRNA levels was transient because levels were not reduced after 1 week of treatment with the PGE1 analog. Thus, while the beneficial effects of chronic treatment with E-series prostaglandins in MRL-lpr/lpr mice may be mediated by other mechanisms, these data suggest than an important short-term effect of misoprostol in this model may be suppression of renal cortical IL-1P mRNA levels.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalClinical Immunology and Immunopathology
Volume75
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Synthetic Prostaglandins
Misoprostol
Lupus Nephritis
Alprostadil
Kidney
Prostaglandins E
Messenger RNA
Interleukin-1
Densitometry
Therapeutics
Thromboxane B2
Leukotriene B4
Eicosanoids
Nephritis
Subcutaneous Injections
Dinoprostone
Systemic Lupus Erythematosus
Autoimmune Diseases
Cytokines
Survival

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

The effects of short-term treatment with the prostaglandin E1 (PGE1) analog misoprostol on inflammatory mediator production in murine lupus nephritis. / Fan, P. Y.; Ruiz, Phillip; Pisetsky, D. S.; Spurney, R. F.

In: Clinical Immunology and Immunopathology, Vol. 75, No. 2, 01.01.1995, p. 125-130.

Research output: Contribution to journalArticle

@article{9038f3cacf3543ef88795c2ee346650a,
title = "The effects of short-term treatment with the prostaglandin E1 (PGE1) analog misoprostol on inflammatory mediator production in murine lupus nephritis",
abstract = "MRL-lpr/lpr mice spontaneously develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus. In these animals, treatment with E-series prostaglandins ameliorates renal disease and prolongs survival, perhaps by modulating production of cytokines or eicosanoids. To further define the mechanisms of action of E-series prostaglandins in established murine lupus nephritis, we administered the prostaglandin E, (PGE1) analog misoprostol to 20-week-old MRL-lpr/lpr mice by twice-daily subcutaneous injection. After 2 days of treatment, misoprostol reduced renal cortical interleukin-1β (IL-1P) mRNA levels compared to vehicle-treated controls (0.19 ± 0.06 (misoprostol) vs 0.50 ± 0.04 (vehicle) densitometry units; P < 0.005). A similar reduction in cortical IL-1P mRNA levels was found in left kidneys harvested from MRL-lpr/lpr mice following 2 days of treatment with misoprostol compared to right kidneys harvested from the same animal prior to the first dose of PGE1, analog (0.12 ± .05 (left) vs 0.39 ± 0.18 (right) densitometry units; P < 0.05). This reduction in cortical IL-1β mRNA levels was not associated with alterations in renal production of thromboxane B2, PGE2, or leukotriene B4 or with significant changes in the severity of renal inflammatory cell infiltrates. Timecourse studies indicated that IL-1P mRNA levels were decreased within 24 hr of initiating misoprostol therapy. This reduction in IL-1β mRNA levels was transient because levels were not reduced after 1 week of treatment with the PGE1 analog. Thus, while the beneficial effects of chronic treatment with E-series prostaglandins in MRL-lpr/lpr mice may be mediated by other mechanisms, these data suggest than an important short-term effect of misoprostol in this model may be suppression of renal cortical IL-1P mRNA levels.",
author = "Fan, {P. Y.} and Phillip Ruiz and Pisetsky, {D. S.} and Spurney, {R. F.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1006/clin.1995.1061",
language = "English",
volume = "75",
pages = "125--130",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The effects of short-term treatment with the prostaglandin E1 (PGE1) analog misoprostol on inflammatory mediator production in murine lupus nephritis

AU - Fan, P. Y.

AU - Ruiz, Phillip

AU - Pisetsky, D. S.

AU - Spurney, R. F.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - MRL-lpr/lpr mice spontaneously develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus. In these animals, treatment with E-series prostaglandins ameliorates renal disease and prolongs survival, perhaps by modulating production of cytokines or eicosanoids. To further define the mechanisms of action of E-series prostaglandins in established murine lupus nephritis, we administered the prostaglandin E, (PGE1) analog misoprostol to 20-week-old MRL-lpr/lpr mice by twice-daily subcutaneous injection. After 2 days of treatment, misoprostol reduced renal cortical interleukin-1β (IL-1P) mRNA levels compared to vehicle-treated controls (0.19 ± 0.06 (misoprostol) vs 0.50 ± 0.04 (vehicle) densitometry units; P < 0.005). A similar reduction in cortical IL-1P mRNA levels was found in left kidneys harvested from MRL-lpr/lpr mice following 2 days of treatment with misoprostol compared to right kidneys harvested from the same animal prior to the first dose of PGE1, analog (0.12 ± .05 (left) vs 0.39 ± 0.18 (right) densitometry units; P < 0.05). This reduction in cortical IL-1β mRNA levels was not associated with alterations in renal production of thromboxane B2, PGE2, or leukotriene B4 or with significant changes in the severity of renal inflammatory cell infiltrates. Timecourse studies indicated that IL-1P mRNA levels were decreased within 24 hr of initiating misoprostol therapy. This reduction in IL-1β mRNA levels was transient because levels were not reduced after 1 week of treatment with the PGE1 analog. Thus, while the beneficial effects of chronic treatment with E-series prostaglandins in MRL-lpr/lpr mice may be mediated by other mechanisms, these data suggest than an important short-term effect of misoprostol in this model may be suppression of renal cortical IL-1P mRNA levels.

AB - MRL-lpr/lpr mice spontaneously develop an autoimmune disease with nephritis similar to human systemic lupus erythematosus. In these animals, treatment with E-series prostaglandins ameliorates renal disease and prolongs survival, perhaps by modulating production of cytokines or eicosanoids. To further define the mechanisms of action of E-series prostaglandins in established murine lupus nephritis, we administered the prostaglandin E, (PGE1) analog misoprostol to 20-week-old MRL-lpr/lpr mice by twice-daily subcutaneous injection. After 2 days of treatment, misoprostol reduced renal cortical interleukin-1β (IL-1P) mRNA levels compared to vehicle-treated controls (0.19 ± 0.06 (misoprostol) vs 0.50 ± 0.04 (vehicle) densitometry units; P < 0.005). A similar reduction in cortical IL-1P mRNA levels was found in left kidneys harvested from MRL-lpr/lpr mice following 2 days of treatment with misoprostol compared to right kidneys harvested from the same animal prior to the first dose of PGE1, analog (0.12 ± .05 (left) vs 0.39 ± 0.18 (right) densitometry units; P < 0.05). This reduction in cortical IL-1β mRNA levels was not associated with alterations in renal production of thromboxane B2, PGE2, or leukotriene B4 or with significant changes in the severity of renal inflammatory cell infiltrates. Timecourse studies indicated that IL-1P mRNA levels were decreased within 24 hr of initiating misoprostol therapy. This reduction in IL-1β mRNA levels was transient because levels were not reduced after 1 week of treatment with the PGE1 analog. Thus, while the beneficial effects of chronic treatment with E-series prostaglandins in MRL-lpr/lpr mice may be mediated by other mechanisms, these data suggest than an important short-term effect of misoprostol in this model may be suppression of renal cortical IL-1P mRNA levels.

UR - http://www.scopus.com/inward/record.url?scp=0028963603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028963603&partnerID=8YFLogxK

U2 - 10.1006/clin.1995.1061

DO - 10.1006/clin.1995.1061

M3 - Article

C2 - 7704969

AN - SCOPUS:0028963603

VL - 75

SP - 125

EP - 130

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -